Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10470)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
NPTX2
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Responsed Disease | Glioblastoma | ICD-11: 2A00 | ||
Responsed Drug | Boric Acid | Investigative | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
In Vitro Model |
C6 cells | Malignant glioma | Rattus norvegicus | CVCL_0194 |
Response regulation | Our hypothesis and results provided proof that boric acid prevent tumor progression by regulation of ferroptosis, apoptosis and semaphorin signaling pathway. BA was found to have more effective on SEMA3F/NP2 upregulated against C6 untreated cells. What's more, the novel anticancer candidate drug effect of BA were principally associated with the ACSL4/GPX4, TOS/TAS biochemical marker and SEMA3F/NP2 signaling pathways. Dose-decently BA induced oxidative and ferroptosis Glioblastoma multiform. | |||
Glioblastoma [ICD-11: 2A00]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Neuronal pentraxin-2 (NPTX2) | Protein coding | ||
Responsed Drug | Boric Acid | Investigative | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
In Vitro Model |
C6 cells | Malignant glioma | Rattus norvegicus | CVCL_0194 |
Response regulation | Our hypothesis and results provided proof that boric acid prevent tumor progression by regulation of ferroptosis, apoptosis and semaphorin signaling pathway. BA was found to have more effective on SEMA3F/NP2 upregulated against C6 untreated cells. What's more, the novel anticancer candidate drug effect of BA were principally associated with the ACSL4/GPX4, TOS/TAS biochemical marker and SEMA3F/NP2 signaling pathways. Dose-decently BA induced oxidative and ferroptosis Glioblastoma multiform. | |||
Boric Acid
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Unspecific Target | |||
Responsed Disease | Glioblastoma | ICD-11: 2A00 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
In Vitro Model |
C6 cells | Malignant glioma | Rattus norvegicus | CVCL_0194 |
Response regulation | Our hypothesis and results provided proof that boric acid prevent tumor progression by regulation of ferroptosis, apoptosis and semaphorin signaling pathway. BA was found to have more effective on SEMA3F/NP2 upregulated against C6 untreated cells. What's more, the novel anticancer candidate drug effect of BA were principally associated with the ACSL4/GPX4, TOS/TAS biochemical marker and SEMA3F/NP2 signaling pathways. Dose-decently BA induced oxidative and ferroptosis Glioblastoma multiform. | |||